Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2021 · 10-Q
Revenue$5.77M$5.77M+22.0% vs Q2 2020 Net Income$120.00K$120.00KN/M vs Q2 2020 EPS Diluted$0.06$0.06N/M vs Q2 2020 Gross Profit$2,502,000+15.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$357,000N/M Free Cash Flowderived-$402,000N/M Margins · derivedGross margin43.4%−2.6 pt vs Q2 2020
Operating margin2.9%+30.2 pt vs Q2 2020
Net margin2.1%+27.5 pt vs Q2 2020
ended Sep 30, 2020 · filed Nov 20, 2020 · 51 d after period end